These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 25778781)
1. Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC). Zhao Q; Gu X; Zhang C; Lu Q; Chen H; Xu L Cancer Biol Ther; 2015; 16(4):634-43. PubMed ID: 25778781 [TBL] [Abstract][Full Text] [Related]
2. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823 [TBL] [Abstract][Full Text] [Related]
3. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Song P; Sekhon HS; Lu A; Arredondo J; Sauer D; Gravett C; Mark GP; Grando SA; Spindel ER Cancer Res; 2007 Apr; 67(8):3936-44. PubMed ID: 17440109 [TBL] [Abstract][Full Text] [Related]
4. SSPH I, A Novel Anti-cancer Saponin, Inhibits EMT and Invasion and Migration of NSCLC by Suppressing MAPK/ERK1/2 and PI3K/AKT/ mTOR Signaling Pathways. Zhou J; Luo J; Gan R; Zhi L; Zhou H; Lv M; Huang Y; Liang G Recent Pat Anticancer Drug Discov; 2024; 19(4):543-555. PubMed ID: 38305308 [TBL] [Abstract][Full Text] [Related]
5. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Carlisle DL; Liu X; Hopkins TM; Swick MC; Dhir R; Siegfried JM Pulm Pharmacol Ther; 2007; 20(6):629-41. PubMed ID: 17015027 [TBL] [Abstract][Full Text] [Related]
6. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Wang ZL; Fan ZQ; Jiang HD; Qu JM Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT. Zhao YY; Jia J; Zhang JJ; Xun YP; Xie SJ; Liang JF; Guo HG; Zhu JZ; Ma SL; Zhang SR Acta Pharmacol Sin; 2021 Aug; 42(8):1288-1297. PubMed ID: 33159174 [TBL] [Abstract][Full Text] [Related]
8. Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway. Xu R; Shang C; Zhao J; Han Y; Liu J; Chen K; Shi W Tumour Biol; 2015 Jun; 36(6):4091-100. PubMed ID: 25964092 [TBL] [Abstract][Full Text] [Related]
9. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Song P; Sekhon HS; Fu XW; Maier M; Jia Y; Duan J; Proskosil BJ; Gravett C; Lindstrom J; Mark GP; Saha S; Spindel ER Cancer Res; 2008 Jun; 68(12):4693-700. PubMed ID: 18559515 [TBL] [Abstract][Full Text] [Related]
10. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways. Jiang M; Zhou LY; Xu N; An Q Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884 [TBL] [Abstract][Full Text] [Related]
11. Isorhamnetin inhibited migration and invasion via suppression of Akt/ERK-mediated epithelial-to-mesenchymal transition (EMT) in A549 human non-small-cell lung cancer cells. Luo W; Liu Q; Jiang N; Li M; Shi L Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31467176 [TBL] [Abstract][Full Text] [Related]
12. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Fujiwara A; Shintani Y; Funaki S; Kawamura T; Kimura T; Minami M; Okumura M Lung Cancer; 2017 Apr; 106():8-16. PubMed ID: 28285699 [TBL] [Abstract][Full Text] [Related]
13. The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells. Kucuksayan H; Akca H Tumour Biol; 2017 Sep; 39(9):1010428317706212. PubMed ID: 28937318 [TBL] [Abstract][Full Text] [Related]
14. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer. Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892 [TBL] [Abstract][Full Text] [Related]
15. Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells. Nonpanya N; Prakhongcheep O; Petsri K; Jitjaicham C; Tungsukruthai S; Sritularak B; Chanvorachote P Anticancer Res; 2020 Sep; 40(9):4989-4999. PubMed ID: 32878787 [TBL] [Abstract][Full Text] [Related]
16. Sirtuin 7 promotes non‑small cell lung cancer progression by facilitating G1/S phase and epithelial‑mesenchymal transition and activating AKT and ERK1/2 signaling. Zhao Y; Ye X; Chen R; Gao Q; Zhao D; Ling C; Qian Y; Xu C; Tao M; Xie Y Oncol Rep; 2020 Sep; 44(3):959-972. PubMed ID: 32705247 [TBL] [Abstract][Full Text] [Related]
17. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Buonato JM; Lazzara MJ Cancer Res; 2014 Jan; 74(1):309-19. PubMed ID: 24108744 [TBL] [Abstract][Full Text] [Related]
18. Knockdown of SP1/Syncytin1 axis inhibits the proliferation and metastasis through the AKT and ERK1/2 signaling pathways in non-small cell lung cancer. Li X; Fu Y; Xia X; Zhang X; Xiao K; Zhuang X; Zhang Y Cancer Med; 2019 Sep; 8(12):5750-5759. PubMed ID: 31397118 [TBL] [Abstract][Full Text] [Related]
19. R2-8018 reduces the proliferation and migration of non-small cell lung cancer cells by disturbing transactivation between M3R and EGFR. Lan L; Wang H; Yang R; Liu F; Bi Q; Wang S; Wei X; Yan H; Su R Life Sci; 2019 Oct; 234():116742. PubMed ID: 31401315 [TBL] [Abstract][Full Text] [Related]
20. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling. Liu X; Sun L; Zhang S; Zhang S; Li W J Cell Physiol; 2020 Nov; 235(11):7747-7756. PubMed ID: 31681988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]